Humoral autoimmunity

Advances in Experimental Medicine and Biology

Volumn 552, Issue , 2004, Pages 247-267

  Yu, Liping ^a   Eisenbarth, George S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CARBOXYPEPTIDASE H; GLUCOSE TRANSPORTER; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLYCOLIPID; HEAT SHOCK PROTEIN 65; IMMUNOGLOBULIN G; INSULIN; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PROTEIN TYROSINE PHOSPHATASE; SIALIC ACID;

ANTIGEN ANTIBODY REACTION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; RADIOASSAY; REVIEW; RISK FACTOR; THIN LAYER CHROMATOGRAPHY;

AGE FACTORS; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; GLYCOLIPIDS; HUMANS; ISLETS OF LANGERHANS; MEMBRANE PROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 11844264901     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (151)

1. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia 1999; 42:3-14.
2. Bach JF. Etiology and Pathogenesis of Human Insulin-Dependent Diabetes Mellitus 1999; 293-307.
3. Abiru N, Eisenbarth GS. Autoantibodies and autoantigens in type 1 diabetes: Role in pathogenesis, prediction and prevention. Can J Diabetes Care 1999; 23:59-65.
4. Bonifacio E, Scirpoli M, Kredel K et al. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 1999; 163:525-532.
5. Colman PG, McNair P, Margetts H et al. The Melbourne PreDiabetes Study: Prediction of type 1 diabetes mellitus using antibody and metabolic testing. Med J Aust 1998; 169:81-84.
6. Kulmala P, Savola K, Petersen JS et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes: A population-based study. J Clin Invest 1998; 101:327-336.
7. Bingley PJ, Bonifacio E, Williams AJK et al. Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers. Diabetes 1997; 46:1701-1710.
8. Greenbaum C, Palmer JP, Kuglin B et al. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: Results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 1992; 74:1040-1044.
9. Baekkeskov S, Aanstoot H-J, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published erratum appears in Nature 1990 Oct 25;347(6295):782]. Nature 1990; 347:151-156.
10. Rabin DU, Pleasic SM, Palmer-Crocker R et al. Cloning and expression of IDDM-specific human autoantigens. Diabetes 1992; 41:183-186.
11. Rabin DU, Pleasic SM, Shapiro JA et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 1994; 152:3183-3188.
12. Lan MS, LU J, Goto Y et al. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994; 13:505-514.
13. Wasmeier C, Hutton JC. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 1996; 271:18161-18170.
14. LU J, Li Q, Xie H et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: Precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci USA 1996; 93:2307-2311.
15. Castano L, Russo E, Zhou L et al. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab 1991; 73:1197-1201.
16. Thomas NM, Ginsberg-Fellner F, Mcevoy RC. Strong association between diabetes and displacement of mouse anti-rat insulinoma cell monoclonal antibody by human serum in vitro. Diabetes 1990; 39:1203-1211.
17. Pan Y-X, Thomas NM, Mcevoy RC. Purification and partial characterization of 160 kD and 155 kD B cell membrane antigens detected by MAb 1A2. Autoimmunity 1993; 15:Suppl:77A.
18. Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a β-cell antigen. J Immunol 1993; 150:3080-3085.
19. r autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 1993; 22:240-248.
20. Roep BO, Kallan AA, Hazenbos WLW et al. T-cell reactivity to 38kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet 1991; 337:1439-1441.
21. Pietropaolo M, Gianani R, Yu L et al. Independent expression of biochemically determined autoantibodies (can we do away with ICA?). Autoimmunity 1993.
22. Pietropaolo M, Castano L, Babu S et al. Islet cell autoantigen 69 kDa (ICA69): Molecular cloning and characterization of a novel diabetes associated autoantigen. J Clin Invest 1993; 92:359-371.
23. Birk OS, Elias D, Weiss AS et al. NOD mouse diabetes: The ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996; 9:159-166.
24. Elias D, Cohen I, Shechter Y et al. Antibodies to insulin receptor followed by anti-idiotype. Diabetes 1987; 36:348-354.
25. Georgopoulos C, McFarland H. Heat shock proteins in multiple sclerosis and other autoimmune diseases. Immunol Today 1993; 14:373-375.
26. Atkinson MA, Maclaren NK, Scharp DW. No evidence for HSP65 in insulin dependent diabetes. Lancet 1990; 337:263-264.
27. Lernmark Å, Freedman ZR, Hofmann C et al. Islet-cell-surface antibodies in juvenile diabetes mellitus. N Engl J Med 1978; 299:375-380.
28. Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-1040.
29. Nerup J. Addison's disease - clinical studies: A report of 108 cases. Acta Endocrinol 1974; 76:127-141.
30. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2:1279-1283.
31. Eizirik L, Sandler S, Palmer JP. Repair of pancreatic β-cells: A relevant phenomenon in early IDDM? Diabetes 1993; 42:1383-1391.
32. Thai A-C, Eisenbarth GS. Natural history of IDDM. Diabetes Rev 1993; 1:1-14.
33. Turner R, Stratton I, Horton V et al. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350:1288-1293.
34. Greenbaum CJ, Palmer JP, Nagataki S et al. Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Exhange Workshop. Diabetes 1992; 41:1570-1574.
35. Gianani R, Pugliese A, Bonner-Weir S et al. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 1992; 41:347-353.
36. Genovese S, Bonifacio E, McNally JM et al. Distinct cytoplasmic islet cell antibodies with different risks for type I (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35:385-388.
37. Solimena M, Folli F, Denis-Donini S et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy and type I diabetes mellitus. N Engl J Med 1988; 318:1012-1020.
38. Colman PG, Nayak RC, Campbell IL et al. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 1988; 37:645-652.
39. Erdo SL, Wolff JR. Gamma-aminobutyric acid outside the mammalian brain. J Neurochem 1990; 54:363-372.
40. Petersen JS, Russel S, Marshall MO et al. Differential expression of glutamic acid decarboxylase in rat and human islets. Diabetes 1993; 42:484-495.
41. Kim J, Richter W, Aanstoot HJ et al. Differential expression of GAD65 and GAD67 in human, rat and mouse pancreatic islets. Diabetes 1993; 42:1799-1808.
42. Eisenbarth GS. Mouse or man: Is GAD the cause of type I diabetes? Diabetes Care 1994; 17:1-3.
43. Christie M, Landin-Olsson M, Sundkvist G et al. Antibodies to a Mr-64,000 islet cell protein in Swedish children with newly diagnosed type I (insulin-dependent) diabetes. Diabetologia 1988; 31:597-602.
44. Baekkeskov S, Landin M, Kristensen JK et al. Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest 1987; 79:926-934.
45. Gianani R, Jackson R, Eisenbarth GS. Evidence that the autoantigen of restricted ICA is GAD. Diabetes Res Clin Prac 1991; 14(suppl1):S13.
46. Velloso LA, Kampe O, Hallberg A et al. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 1993; 91:2084-2090.
47. Verge CF, Stenger D, Bonifacio E et al. Combined use of autoantibodies (IA-2ab, Gadab, IAA, ICA) in type 1 diabetes: Combinatorial islet autoantibody workshop. Diabetes 1998; 47:1857-1866.
48. Harrison LC, Honeyman MC, DeAizpurua HJ et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341:1365-1369.
49. Bu DF, Tobin AJ. The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD. Genomics 1994; 21:222-228.
50. Verge CF, Gianani R, Kawasaki E et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926-933.
51. Hagopian WA, Michelsen B, Karlsen AE et al. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes 1993; 42:631-636.
52. Falorni A, Ackefors M, Carlberg C et al. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia 1996; 39:1091-1098.
53. Hallengren B, Falorni A, Landin-Olsson M et al. Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients: At diagnosis and following treatment. J Intern Med 1996; 239:63-68.
54. Richter W, Endl J, Eiermann TH et al. Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen. Proc Natl Acad Sci USA 1992; 89:8467-8471.
55. Richter W, Seissler J, Northemann W et al. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome. Diabetes 1993; 42:1642-1648.
56. Syren K, Lindsay L, Stoehrer B et al. Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 1996; 157:5208-5214.
57. Daw K, Powers AC. Two distinct glutamic acid decarboxylase autoantibody specificities in IDDM target different epitopes. Diabetes 1995; 44:216-220.
58. Schwartz HL, Chandonia JM, Kash SF et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 1999; 287:983-999.
59. Ujihara N, Daw K, Gianani R et al. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes. Diabetes 1994; 43:968-975.
60. Butler MH, Solimena M, Dirkx R et al. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178:2097.
61. Kim J, Namchuk M, Bugawan T et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994; 180:595-606.
62. Daw K, Ujihara N, Atkinson M et al. Glutamic acid decarboxylase autoantibodies in Stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996; 156:818-825.
63. Bjork E, Velloso LA, Kampe O et al. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 1994; 43:161-165.
64. Powers AC, Bavik K, Tremble J et al. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin Exp Immunol 1999; 118:349-356.
65. Christie MR, Tun RYM, Lo SSS et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM: Studies with identical twins. Diabetes 1992; 41:782-787.
66. Christie MR, Genovese S, Cassidy D et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994; 43:1254-1259.
67. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000- and 40,000-M, tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995; 96:1506-1511.
68. Kawasaki E, Yu L, Rewers MJ et al. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998; 47:733-742.
69. Gianani R, Rabin DU, Verge CF et al. ICA512 autoantibody radioassay. Diabetes 1995; 44:1340-1344.
70. Kawasaki E, Yu L, Gianani R et al. Evaluation of islet cell antigen (ICA) 512/IA-2 autoantibody radioassays using overlapping ICA512/IA-2 constructs. J Clin Endocrinol Metab 1997; 82:375-380.
71. Farilla L, Tiberti C, Luzzago A et al. ICA512bdc cDNA expression library displayed on the capsid protein D of bacteriophage lambda: A novel strategy to identify major antigenic epitopes in autoimmune diseases. 1999.
72. Ziegler A-G, Hummel M, Schenker M et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes. The 2-year analysis of the German BABYDIAB study. Diabetes 1999; 48:460-468.
73. Kundu SK, Pleatman MA, Redwine WA et al. Binding of monoclonal antibody A2B5 to gangliosides. Biochem Biophys Res Commun 1983; 116:836-842.
74. Nayak RC, Attawia NA, Cahill CJ et al. Expression of a monoclonal antibody (3G5) defined ganglioside antigen in renal cortex. Kidney Int 1992; 41:1638-1645.
75. Alejandro R, Shienvold FL, Hajek SAV et al. A ganglioside antigen on the rat pancreatic B cell surrace identified by monoclonal antibody R2D6. J Clin Invest 1984; 74:25-38.
76. Srikanta S, Krisch K, Eisenbarth GS. Islet cell proteins defined by monoclonal islet cell antibody HISL-19. Diabetes 1986; 35:300-305.
77. Srikanta S, Telen M, Posillico JT et al. Monoclonal antibodies to a human islet cell surface glycoprotein: 4F2 and LC7-2. Endocrinology 1987; 120:2240-2244.
78. Gillard BK, Thomas JW, Nell LJ et al. Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus. J Immunol Methods 1989; 142:3826-3832.
79. Buschard K, Josefsen K, Horn T et al. Sulphatide and anti-sulphatide antibodies in type I diabetes mellitus. Diabetes 1993; 42(Suppl 1):5A.
80. Dotta F, Previti M, Lenti L et al. GM2-1 pancreatic islet ganglioside: Identification and characterization of a novel islet-specific molecule. Diabetologia 1995; 38:1117-1121.
81. Dotta F, Gianani R, Dionisi S et al. Expression of anti-GM2-1 islet ganglioside antibodies in ICA+ relatives of type I diabetics. Autoimmunity 1993; 15(suppl):70-70.
82. Folkman S, Lazarus RS. 1988; 1.
83. Dotta F, Colman PG, Lombardi D et al. Ganglioside expression in human pancreatic islets. Diabetes 1989; 38:1478-1483.
84. Dotta F, Previti M, Tiberti C et al. Identification of the GM2-1 islet ganglioside: Similarities with a major neuronal autoantigen. Diabetes 1992; 41:365A-
85. Pugliese A, Zeller M, Fernandez A et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type I diabetes. Nat Genet 1997; 15:293-297.
86. Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: Factors in self- tolerance and autoimmunity. Curr Opin Immunol 1998; 10:656-662.
87. Davidson HW, Hutton JC. The insulin-secretory-granule carboxypeptidase H. Biochem J 1993; 245:575-582.
88. Berson SA, Yallow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 1959; 38:1996-2016.
89. Davidson JK, DeBra DW. Immunologic insulin resistance. Diabetes 1978; 27:307-318.
90. Hirata Y, Tominaga M, Ito J et al. Spontaneous hypoglycaemia with insulin autoimmunity in Graves' disease. Ann Intern Med 1974; 81:214-218.
91. Uchigata Y, Kuwata S, Tsushima T et al. Patients with Graves' disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406. J Clin Endocrinol Metab 1993; 77:249-254.
92. Uchigata Y, Hirata Y. Insulin Autoimmune Syndrome (IAS, Hirata Disease) 1999; 133-148.
93. Ziegler AG, Vardi P, Gross DJ et al. Production of insulin antibodies by mice rejecting insulin transfected cells. J Autoimmun 1989; 2:219-227.
94. Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222:1337-1339.
95. Castano L, Ziegler AG, Ziegler R et al. Characterization of insulin autoantibodies in relatives of patients with type 1 diabetes. Diabetes 1993; 42:1202-1209.
96. Pugliese A, Bugawan T, Moromisato R et al. Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes. J Clin Invest 1994; 93:2447-2452.
97. Vardi P, Ziegler AG, Matthews JH et al. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diabetes Care 1988; 11:736-739.
98. Williams AJK, Bingley PJ, Bonifacio E et al. A novel micro-assay for insulin autoantibodies. J Autoimmun 1997; 10:473-478.
99. Bilbao JR, Calvo B, Urrutia I et al. Anti-insulin activity in normal newborn cord-blood serum
100. Absence of IgG-mediated insulin binding. Diabetes 1997; 46:713-716.
101. Naserke HE, Bonifacio E, Ziegler A-G. Immunoglobulin G insulin autoantibodies in BABYDIAB offspring appear postnatally: Sensitive early detection using a protein A/G-based radiobinding assay. J Clin Endocrinol Metab 1999; 84:1239-1243.
102. Rosenbauer J, Herzig P, von Kries R et al. Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in children under 5 years of age in Germany. Diabetologia 1999; 42:1055-1059.
103. Yu L, Robles DT, Abiru N et al. Early expression of anti-insulin autoantibodies of man and the NOD mouse: Evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000; 97:1701-1706.
104. Moriyama H, Wen L, Abiru N et al. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci USA 2002; 99(8):5539-5544.
105. Bonifacio E, Atkinson M, Eisenbarth GS et al. International workshop on autoimmunity in animal models of autoimmune diabetes identifies insulin, but not GAD or IA-2 as specific antigens of humoral autoimmunity in the nonobese diabetic mouse. Diab 2001; 50:2451-2458.
106. Abiru N, Maniatis AK, Yu L et al. Peptide and MHC Specific Breaking of Humoral Tolerance to Native Insulin with the B:9-23 Peptide in Diabetes Prone and Normal Mice. Diabetes 2001; 50:1274-1281.
107. Rojas M, Hulbert C, Thomas JW. Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen. J Immunol 2001; 166:3194-3200.
108. Bellward GD, Chang T, Rodrigues B et al. Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. Mol Pharmacol 1988; 33:140-143.
109. Pugliese A, Brown D, Garza D et al. Self-Antigen Presenting Cells Expressing Islet Cell Molecules in Human Thymus and Peripheral Lymphoid Organs: Phenotypic Characterization and Implications for Immunological Tolerance and Type 1 Diabetes. J Clin Invest 2001; 107:555-564.
110. Li L, Hagopian WA, Brashear HR et al. Identification of autoantibody epitopes of glutamic acid decarboxylase in stiff-man syndrome patients. J Immunol 1994; 152:930-934.
111. Stassi G, Schloot N, Pietropaolo M. Islet cell autoantigen 69 kDa (ICA69) is preferentially expressed in the human islets of Langerhans than exocrine pancreas. Diabetologia 1997; 40:120-121.
112. Spitzenberger F, Pietropaolo S, Verkade P et al. Islet cell autoantigen of 69 kDa is an arfaptin-related protein associated with the golgi complex of insulinoma INS-1 cells. J Biol Chem 2003; 278(28):26166-26173.
113. Karges W, Gaedigk R, Hui MF et al. Molecular cloning of murine ICA69: Diabetes-prone mice recognize the human autoimmune-epitope, Tep69, conserved in splice variants from both species. Biochim Biophys Acta 1997; 1360:97-101.
114. Martin S, Kardorf J, Schulte B et al. Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis. Diabetologia 1995; 38:351-355.
115. Atkinson MA, Bowman MA, Kao K et al. Lack of immune responsiveness to bovine serum albumin in insulin- dependent diabetes. N Engl J Med 1993; 329:1853-1858.
116. Winer S, Gunaratnam L, Astsatourov I et al. Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes. J Immunol 2000; 165:4086-4094.
117. Fida S, Myers MA, Whittingham S et al. Autoantibodies to the transcriptional factor SOX13 in primary biliary cirrhosis compared with other diseases. J Autoimmun 2002; 19(4):251-257.
118. Karounos DG, Simmerman L, Hickman SL et al. Identification of the p52-Rubella related autoantigen as an insulin secretory granule protein. Diabetes 1993; 42(Suppl 1):221A.
119. Honeyman MC, Cram DS, Harrison LC. Transcription factor jun-B is target of autoreactive T-cells in IDDM. Diabetes 1993; 42:626-630.
120. Pak CY, Cha CY, Rajotte RV et al. Human pancreatic islet cell specific 38 kilodalton autoantigen identified by cytomegalovirus-induced monoclonal islet cell autoantibody. Diabetologia 1990; 33:569-572.
121. Arden SD, Roep BO, Neophytou PI et al. Imogen 38: A novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type I diabetic patient. J Clin Invest 1996; 97:551-561.
122. Mcevoy RC, Thomas NM, Greig F et al. Anti-islet autoantibodies detected by monoclonalantibody 1A2: Further studies suggesting a role in the pathogenesis of IDDM. Diabetologia 1996; 39:1365-1371.
123. Aanstoot H-J, Kang S-M, Kim J et al. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of au-toimmune response in type I diabetes. J Clin Invest 1996; 97:2772-2783.
124. Roll U, Turck CW, Gitelman SE et al. Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients. Diabetol 2000; 43(5):598-608.
125. Birk OS, Elias D, Weiss AS et al. NOD mouse diabetes: The ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996; 9:159-166.
126. Elias D, Reshef T, Birk OS et al. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991; 88:3088-3091.
127. Jones DB, Hunter NR, Duff GW. Heat-shock protein 65 as a B cell antigen of insulin-dependent diabetes. Lancet 1990; 336:583-585.
128. Elias D, Meilin A, Ablamunits V et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various β-cell antigens. Diabetes 1997; 46:758-764.
129. Johnson JH, Crider BP, McCorkle K et al. Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med 1990; 322:653-659.
130. Inman LR, McAllister CT, Chen L et al. Autoantibodies to the GLUT-2 glucose transporter of β cells in insulin-dependent diabetes mellitus of recent onset. Proc Natl Acad Sci USA 1993; 90:1281-1284.
131. Roep BO, Atkinson MA, Van Endert PM et al. Autoreactive T cell responses in Insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun 1999; 13:267-282.
132. Atkinson MA, Kaufman DL, Campbell L et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992; 339:458-459.
133. Atkinson MA, Bowman MA, Campbell L et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94:2125-2129.
134. Harrison LC, Chu SX, DeAizpurua HJ et al. Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes. J Clin Invest 1992; 89:1161-1165.
135. Kaufman DL, ClareSalzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin dependent diabetes. Nature 1993; 366:69-72.
136. Tisch R, Yang X-D, Singer SM et al. Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice. Nature 1993; 366:72-75.
137. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999; 163:1178-1187.
138. Nepom GT, Lippolis JD, White FM et al. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci USA 2001; 98:1763-1768.
139. Lieberman SM, Evans AM, Han B et al. Identification of the {beta} cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 2003; 100(14):8384-8388.
140. Karjalainen J, Cheung R, Vandermeulen JM et al. T cell proliferation response against bovine albumin (BSA) follows the natural course and is restricted to the linear ABBOS sequence in insulin-dependent diabetes mellitus. Autoimmunity 1993; 15 Supplement:62A.
141. Hummel M, Durinovic-Bello I, and Ziegler A-G. Relation between cellular and humoral immunity to islet cell antigens in type I diabetes. J Autoimmun 1996; 9:427-430.
142. Kelemen K, Crawford ML, Gill RG et al. Cellular immune response to phogrin in the NOD mouse: Cloned T-cells cause destruction of islet transplants. Diabetes 1999; 48:1529-1534.
143. Roep BO, Arden SD, deVries RP et al. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990; 345:632-634.
144. Van Vliet E, Roep BO, Meulenbroek L et al. Human T cell clones with specificity for insulinoma cell antigens. Eur J Immunol 1989; 19:213-216.
145. Keller RJ. Cellular immunity to human insulin in individuals at high risk for the development of type 1 diabetes mellitus. J Autoimmun 1990; 3:321-327.
146. Abiru N, Wegmann D, Kawasaki E et al. Dual overlapping peptides recognized by insulin peptide B:9-23 reactive T cell receptor AV13S3 T cell clones of the NOD mouse. J Autoimmun 2000; 14:231-237.
147. Daniel D, Gill RG, Schloot N et al. Epitope specificity, cytokine production profile and diabeto-genic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995; 25:1056-1062.
148. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93:956-960.
149. Simone E, Daniel D, Schloot N et al. T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proc Natl Acad Sci USA 1997; 94:2518-2521.
150. Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001; 107:173-180.
151. Bonifacio E, Genovese S, Braghi S et al. Islet autoantibody markers in IDDM: Risk assessment strategies yielding high sensitivity. Diabetologia 1995; 38:816-822.